Bungo Furusato

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9390781/publications.pdf

Version: 2024-02-01

55 papers	3,605 citations	186265 28 h-index	155660 55 g-index
56 all docs	56 docs citations	56 times ranked	4505 citing authors

#	Article	IF	Citations
1	Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERTâ€“Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens. Cancer Research, 2007, 67, 3153-3161.	0.9	344
2	Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene, 2005, 24, 3847-3852.	5.9	326
3	CXCR4 and cancer. Pathology International, 2010, 60, 497-505.	1.3	255
4	Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue. Molecular and Cellular Proteomics, 2005, 4, 1741-1753.	3.8	251
5	ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer and Prostatic Diseases, 2010, 13, 228-237.	3.9	227
6	TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene, 2008, 27, 5348-5353.	5.9	218
7	PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension and Tumor Volume. Journal of Urology, 2008, 180, 1975-1979.	0.4	160
8	Orbital solitary fibrous tumor: encompassing terminology for hemangiopericytoma, giant cell angiofibroma, and fibrous histiocytoma of the orbit: reappraisal of 41 cases. Human Pathology, 2011, 42, 120-128.	2.0	143
9	Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer and Prostatic Diseases, 2010, 13, 311-315.	3.9	139
10	Mapping of TMPRSS2â€“ERG fusions in the context of multi-focal prostate cancer. Modern Pathology, 2008, 21, 67-75.	5.5	123
11	Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2333-2344.	2.5	121
12	Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Modern Pathology, 2011, 24, 1128-1138.	5.5	106
13	Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer. Clinical Cancer Research, 2008, 14, 4719-4725.	7.0	90
14	Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Experimental Cell Research, 2006, 312, 831-843.	2.6	75
15	Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer and Prostatic Diseases, 2012, 15, 150-156.	3.9	63
16	Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer. Clinical Cancer Research, 2010, 16, 1572-1576.	7.0	58
17	Ultrasound-accelerated formalin fixation of tissue improves morphology, antigen and mRNA preservation. Modern Pathology, 2005, 18, 850-863.	5.5	51
18	Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer and Prostatic Diseases, 2006, 9, 56-61.	3.9	51

#	Article	IF	Citations
19	The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate, 2009, 69, 1398-1403.	2.3	50
20	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology, 2019, 51, 463-473.	0.6	47
21	Targeted Disruption of Ing2 Results in Defective Spermatogenesis and Development of Soft-Tissue Sarcomas. PLoS ONE, 2010, 5, e15541.	2.5	43
22	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 409-418.	2.8	42
23	Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1-8.	2.5	38
24	Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells. Experimental Cell Research, 2008, 314, 92-102.	2.6	36
25	Higher Tumor to Benign Ratio of the Androgen Receptor mRNA Expression Associates with Prostate Cancer Progression after Radical Prostatectomy. Urology, 2007, 70, 1225-1229.	1.0	32
26	Use of Step-Section Histopathology to Evaluate ¹⁸ F-Fluorocholine PET Sextant Localization of Prostate Cancer. Molecular Imaging, 2008, 7, 7290.2008.00002.	1.4	30
27	Clinicopathological Behavior of Single Focus Prostate Adenocarcinoma. Journal of Urology, 2009, 182, 2689-2694.	0.4	29
28	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.6	29
29	Immunohistochemical ETSâ€related gene detection in a Japanese prostate cancer cohort: Diagnostic use in Japanese prostate cancer patients. Pathology International, 2011, 61, 409-414.	1.3	28
30	Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses than Seen in the Eosinophilic Subtype. Cancers, 2019, 11, 1492.	3.7	28
31	Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer and Prostatic Diseases, 2008, 11, 194-197.	3.9	27
32	Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan. Prostate, 2014, 74, 321-325.	2.3	27
33	WT1 and Bcl2 Expression in Melanocytic Lesions of the Conjunctiva. JAMA Ophthalmology, 2009, 127, 964.	2.4	25
34	Time Trends in Histological Features of Latent Prostate Cancer in Japan. Journal of Urology, 2016, 195, 1415-1420.	0.4	25
35	Ocular perivascular epithelioid cell tumor: report of 2 cases with distinct clinical presentations. Human Pathology, 2010, 41, 768-772.	2.0	24
36	Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2â€“ERG fusion status. Prostate Cancer and Prostatic Diseases, 2010, 13, 47-51.	3.9	23

#	Article	IF	Citations
37	Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathology International, 2012, 62, 742-748.	1.3	22
38	Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival. Clinical Cancer Research, 2008, 14, 758-763.	7.0	21
39	Evaluation of ERG responsive proteome in prostate cancer. Prostate, 2014, 74, 70-89.	2.3	21
40	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.6	20
41	Allelotyping analysis at chromosome arm 8p of high-grade prostatic intraepithelial neoplasia and incidental, latent, and clinical prostate cancers. Genes Chromosomes and Cancer, 2006, 45, 509-515.	2.8	19
42	Quantitative analysis of a panel of gene expression in prostate cancerâ€"with emphasis on NPY expression analysis. Journal of Zhejiang University: Science B, 2007, 8, 853-859.	2.8	18
43	Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung. Biochemical and Biophysical Research Communications, 2018, 503, 2764-2769.	2.1	15
44	Sarcoidosis of the prostate. Journal of Clinical Pathology, 2006, 60, 325-326.	2.0	14
45	Novel Human Prostate Epithelial Cell Culture Models for the Study of Carcinogenesis and of Normal Stem Cells and Cancer Stem Cells. Advances in Experimental Medicine and Biology, 2011, 720, 71-80.	1.6	14
46	Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men. Prostate, 2019, 79, 3-8.	2.3	12
47	Clinicopathological importance of anterior prostate cancer in Japanese Men. Pathology International, 2017, 67, 156-162.	1.3	10
48	CXCR4 and Cancer. , 2009, , 31-45.		8
49	Benign mimics of prostate cancer. Pathology, 2021, 53, 26-35.	0.6	7
50	Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology, 2021, 78, 342-344.	2.9	6
51	Osteoblast-specific Factor 2 Expression in Prostate Cancer-associated Stroma: Identification Through Microarray Technology. Urology, 2010, 75, 768-772.	1.0	4
52	Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. Pathology International, 2010, 60, 667-672.	1.3	3
53	Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population. Prostate Cancer, 2014, 2014, 1-5.	0.6	3
54	Pathological significance and prognostic role of LATS2 in prostate cancer. Prostate, 2021, 81, 1252-1260.	2.3	2

#	Article	IF	Citations
55	280: Quantitative Features of a Common TMPRSS2-ERG Fusion Transcript in Prostate Cancer. Journal of Urology, 2007, 177, 94-94.	0.4	1